bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim

September 22, 2016 7:46 AM EDT Send to a Friend
Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of bluebird bio (NASDAQ: BLUE) after Mast Therapeutics' (NASDAQ ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login